Benzinga · Apr 10, 2026
UBS Maintains Neutral on QuidelOrtho, Lowers Price Target to $17
UBS analyst Lu Li maintains QuidelOrtho (NASDAQ:QDEL) with a Neutral and lowers the price target from $30 to $17.
QD
NASDAQ · QDEL
QuidelOrtho Corporation
Healthcare · Medical - Instruments & Supplies
$13.97
Up+$0.04 (+0.29%)
Updated Sep 5, 2026, 4:57 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.01B
- P/E ratio
- -1.71
- Dividend yield
- 0.00%
- 52-week range
- $9.92 – $35.58
- Volume
- 890.26K
- Avg. volume
- 1.41M
Price performance
QDEL price history
1M range · 21 trading sessions · Daily adjusted prices
QDEL closed at $13.97 after 21 trading sessions, up 13.72% for the selected period.
- Last close
- $13.97
- Period change
- +13.72%
- Period low
- $12.29
- Period high
- $15.32
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $13.92 | $14.30 | $13.51 | $13.97 | 890.26K |
| Sep 3, 2026 | $14.10 | $14.43 | $13.59 | $13.93 | 836.79K |
| Sep 2, 2026 | $13.67 | $14.28 | $13.67 | $13.95 | 834.46K |
| Sep 1, 2026 | $14.43 | $14.57 | $13.60 | $13.75 | 892.84K |
| Aug 31, 2026 | $14.60 | $14.63 | $14.22 | $14.43 | 948.55K |
| Aug 28, 2026 | $15.09 | $15.105 | $14.62 | $14.74 | 1.21M |
| Aug 27, 2026 | $14.92 | $15.50 | $14.92 | $15.32 | 816.14K |
| Aug 26, 2026 | $15.09 | $15.09 | $14.5517 | $14.91 | 1.6M |
| Aug 25, 2026 | $14.49 | $15.16 | $14.28 | $15.05 | 987.35K |
| Aug 24, 2026 | $14.74 | $14.925 | $14.175 | $14.49 | 1.04M |
| Aug 21, 2026 | $14.96 | $15.50 | $14.1055 | $14.74 | 2.02M |
| Aug 20, 2026 | $13.63 | $15.20 | $13.51 | $14.85 | 2.51M |
| Aug 19, 2026 | $13.70 | $14.33 | $13.66 | $13.80 | 1.32M |
| Aug 18, 2026 | $14.37 | $14.60 | $13.205 | $13.43 | 1.38M |
| Aug 17, 2026 | $14.07 | $14.70 | $14.07 | $14.58 | 1.24M |
| Aug 14, 2026 | $14.86 | $15.26 | $14.11 | $14.30 | 917.95K |
| Aug 13, 2026 | $14.83 | $15.52 | $14.34 | $15.09 | 1.45M |
| Aug 12, 2026 | $13.78 | $14.93 | $13.72 | $14.83 | 1.95M |
| Aug 11, 2026 | $13.585 | $14.24 | $13.28 | $13.99 | 1.5M |
| Aug 10, 2026 | $12.11 | $13.84 | $12.0657 | $13.75 | 2.81M |
| Aug 7, 2026 | $12.668 | $13.22 | $11.41 | $12.285 | 4.89M |
Latest QDEL news
The latest Smart Investors Daily articles mentioning QDEL.
Stock researchCompany · Overview
QDEL research
Overview
Company profile and research snapshot.
Company profile
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $93.40
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2026 | Citigroup | Neutral | — |
| Jul 1, 2026 | JP Morgan | Underweight | — |
| May 7, 2026 | Jefferies | Hold | — |
| May 6, 2026 | Citigroup | Neutral | — |
| Apr 10, 2026 | UBS | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Mar 3, 2026
QuidelOrtho (QDEL): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, QuidelOrtho’s shares (currently trading at $22.11) have posted a disappointing 19.9% loss, well below the S&P 500’s 6.6% gain. This might have investors contemplating their next move.
Yahoo · Mar 2, 2026
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires
QuidelOrtho Corporation's stock has been falling for multiple years, but after a board member purchased shares, could the stock soon reverse?
Yahoo · Feb 26, 2026
Why The QuidelOrtho (QDEL) Story Is Shifting As Analysts Rework Growth And Valuation Assumptions
The blended fair value estimate for QuidelOrtho shifted from US$38.33 to US$34.67, a change of about 9.5% in the modeled price target. This adjustment sits alongside a split analyst backdrop, with some firms lifting targets and others trimming them as they revisit how quickly growth and profitability assumptions might play out. As you read on, you will see how these moving targets shape the evolving narrative around QuidelOrtho and what to watch next in the research updates. Analyst Price...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
